JP2024543043A5 - - Google Patents
Info
- Publication number
- JP2024543043A5 JP2024543043A5 JP2024526901A JP2024526901A JP2024543043A5 JP 2024543043 A5 JP2024543043 A5 JP 2024543043A5 JP 2024526901 A JP2024526901 A JP 2024526901A JP 2024526901 A JP2024526901 A JP 2024526901A JP 2024543043 A5 JP2024543043 A5 JP 2024543043A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- tumors
- polypeptide
- bispecific polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB202115925 | 2021-11-05 | ||
| GB2115925.6 | 2021-11-05 | ||
| GB2204539.7 | 2022-03-30 | ||
| GBGB2204539.7A GB202204539D0 (en) | 2022-03-30 | 2022-03-30 | Novel peptides |
| GB2212801.1 | 2022-09-02 | ||
| GBGB2212801.1A GB202212801D0 (en) | 2022-09-02 | 2022-09-02 | Novel peptides |
| PCT/EP2022/080861 WO2023079102A2 (en) | 2021-11-05 | 2022-11-04 | Novel peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024543043A JP2024543043A (ja) | 2024-11-19 |
| JP2024543043A5 true JP2024543043A5 (https=) | 2025-11-13 |
Family
ID=84329469
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024526901A Pending JP2024543043A (ja) | 2021-11-05 | 2022-11-04 | 新規ペプチド |
| JP2024526902A Pending JP2024542142A (ja) | 2021-11-05 | 2022-11-04 | 新規ポリペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024526902A Pending JP2024542142A (ja) | 2021-11-05 | 2022-11-04 | 新規ポリペプチド |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11873348B2 (https=) |
| EP (2) | EP4426738A2 (https=) |
| JP (2) | JP2024543043A (https=) |
| KR (2) | KR20240114794A (https=) |
| AU (1) | AU2022381977A1 (https=) |
| CA (1) | CA3237463A1 (https=) |
| IL (1) | IL312556A (https=) |
| MX (1) | MX2024005508A (https=) |
| WO (2) | WO2023079102A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240114794A (ko) * | 2021-11-05 | 2024-07-24 | 엘리게이터 바이오사이언스 에이비 | 신규 펩티드 |
| WO2024213533A1 (en) * | 2023-04-13 | 2024-10-17 | Alligator Bioscience Ab | Combination therapies |
| CN117924468B (zh) * | 2023-12-08 | 2024-09-20 | 南京大学 | 一种靶向登革热病毒ns1蛋白纳米抗体的制备方法和应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| SE459005B (sv) | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
| CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
| ES2692268T5 (en) | 2011-03-29 | 2025-02-26 | Roche Glycart Ag | Antibody fc variants |
| GB201115280D0 (en) * | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
| WO2016172485A2 (en) * | 2015-04-24 | 2016-10-27 | Genentech, Inc. | Multispecific antigen-binding proteins |
| US20190336615A1 (en) * | 2017-01-27 | 2019-11-07 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| GB201820556D0 (en) | 2018-12-17 | 2019-01-30 | Alligator Bioscience Ab | Novel polypeptides |
| CN113677703A (zh) * | 2018-12-17 | 2021-11-19 | 鳄鱼生物科学公司 | 多肽 |
| CN120383671A (zh) * | 2019-09-30 | 2025-07-29 | 阿迪马布有限责任公司 | 被工程化用于优先轻链配对的ch1结构域变体和包括所述ch1结构域变体的多特异性抗体 |
| KR20220103957A (ko) * | 2019-10-23 | 2022-07-25 | 리브젠 바이오파마 홀딩스 리미티드 | 항-cd40 결합 분자 및 이를 포함하는 이중-특이적 항체 |
| MX2022008524A (es) * | 2020-01-09 | 2022-09-21 | Biomunex Pharmaceuticals | Anticuerpos multiespecificos que se unen tanto a linfocitos mait como a celulas tumorales. |
| KR20240114794A (ko) * | 2021-11-05 | 2024-07-24 | 엘리게이터 바이오사이언스 에이비 | 신규 펩티드 |
-
2022
- 2022-11-04 KR KR1020247018934A patent/KR20240114794A/ko active Pending
- 2022-11-04 US US17/980,751 patent/US11873348B2/en active Active
- 2022-11-04 US US18/703,623 patent/US20260001961A1/en active Pending
- 2022-11-04 MX MX2024005508A patent/MX2024005508A/es unknown
- 2022-11-04 WO PCT/EP2022/080861 patent/WO2023079102A2/en not_active Ceased
- 2022-11-04 JP JP2024526901A patent/JP2024543043A/ja active Pending
- 2022-11-04 EP EP22822279.0A patent/EP4426738A2/en active Pending
- 2022-11-04 EP EP22800717.5A patent/EP4426733A2/en active Pending
- 2022-11-04 KR KR1020247018489A patent/KR20240099410A/ko active Pending
- 2022-11-04 AU AU2022381977A patent/AU2022381977A1/en active Pending
- 2022-11-04 CA CA3237463A patent/CA3237463A1/en active Pending
- 2022-11-04 WO PCT/EP2022/080860 patent/WO2023079101A2/en not_active Ceased
- 2022-11-04 JP JP2024526902A patent/JP2024542142A/ja active Pending
- 2022-11-04 IL IL312556A patent/IL312556A/en unknown
-
2023
- 2023-11-13 US US18/507,736 patent/US12448465B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Klein et al. | The present and future of bispecific antibodies for cancer therapy | |
| JP2019523630A5 (https=) | ||
| JP2024543043A5 (https=) | ||
| JP2022515318A5 (https=) | ||
| Chen et al. | Bispecific antibodies in cancer immunotherapy | |
| RU2018139339A (ru) | Новые биспецифические полипептиды против cd137 | |
| JP2022537824A5 (https=) | ||
| TWI908779B (zh) | 引導及導航控制(gnc)抗體樣蛋白質及製造與使用其之方法 | |
| JP7600327B2 (ja) | Ｐｄ－１とｖｅｇｆを標的とした四価二重特異性抗体、その製造方法および用途 | |
| JP2022512891A5 (https=) | ||
| JP2018525382A5 (https=) | ||
| Luo et al. | Design and applications of bispecific heterodimers: molecular imaging and beyond | |
| JP2024539630A5 (https=) | ||
| JP2023523268A (ja) | ヘテロダイマータンパク質 | |
| Hayashi et al. | A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells | |
| JP2019505545A5 (https=) | ||
| Hollander | Bispecific antibodies for cancer therapy | |
| JP2023534959A5 (https=) | ||
| Lee et al. | Effective clearance of rituximab-resistant tumor cells by breaking the mirror-symmetry of immunoglobulin G and simultaneous binding to CD55 and CD20 | |
| WO2021113748A1 (en) | Composition of triaxial antibodies and method of making and using thereof | |
| Asano et al. | Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells | |
| WO2023217216A1 (zh) | 一种三特异性抗体的设计、制备及用途 | |
| JP7505784B2 (ja) | Ｇｄ２結合性分子 | |
| US20260055201A1 (en) | Bispecific antibody and use thereof | |
| CN120035449A (zh) | 一种结合baffr和cd3的双特异性抗体及其应用 |